A new experimental vaccine regimen, tailor made to fit of the structure of a vulnerable region on HIV, generated antibodies in mice, guinea pigs and monkeys, and it neutralized dozens of HIV strains. The findings will lead to human clinical trials for a vaccine capable of neutralizing a large fraction of common HIV strains. The findings were published on June 4th in the journal Nature Medicine, and it was led by investigators from the National Institute of Allergy and Infectious Diseases, which falls under the National Institutes of Health. Chief of the Structural Biology Section at the NIAID Vaccine Research Center Peter D.
Kwong, Ph.D and John R. Mascola, M.D., center director, spearheaded the study. The study has been called “elegant” by research leaders. “NIH scientists have used their detailed knowledge of the structure of HIV to find an unusual site of vulnerability on the virus…
